Torri D Metz1, Amanda A Allshouse2, Anna G Euser3, Kent D Heyborne1. 1. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO; Denver Health Medical Center, Department of Obstetrics and Gynecology, Denver, CO. 2. University of Colorado School of Public Health, Aurora, CO. 3. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO.
Abstract
OBJECTIVE: To determine if early pregnancy serum biomarkers in high-risk women who develop preeclampsia vary according to risk factor. STUDY DESIGN: We performed a secondary analysis of the Maternal-Fetal Medicine Units Network randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in high-risk women. Serum biomarker levels at enrollment (before initiation of aspirin or placebo) were compared between women who did and did not develop preeclampsia, both for the group as a whole and within each of 4 high-risk groups (insulin-dependent diabetes, hypertension, multiple gestation, and previous preeclampsia) using a regression model adjusting for gestational age at collection and prepregnancy body mass index. RESULTS:1258 women were included (233 with insulin-dependent diabetes, 387 with chronic hypertension, 315 with a multiple gestation, 323 with previous preeclampsia). Multiple early pregnancy serum biomarkers differed between women who did and did not develop preeclampsia. Each high-risk group had a unique and largely nonoverlapping pattern of biomarker abnormality. Differences between those who did and did not develop preeclampsia were noted in vascular cell adhesion molecule in the diabetes group; human chorionic gonadotropin, soluble tumor necrosis factor receptor-2, tumor necrosis factor-alpha, selectin and angiogenin in the chronic hypertension group; interleukin-6, placental growth factor, soluble fms-like tyrosine kinase plus endoglin to placental growth factor ratio in the multiple gestation group; and angiogenin in the previous preeclampsia group. CONCLUSION: Patterns of serum biomarkers vary by high-risk group. These data support the hypothesis that multiple pathogenic pathways lead to the disease recognized clinically as preeclampsia.
RCT Entities:
OBJECTIVE: To determine if early pregnancy serum biomarkers in high-risk women who develop preeclampsia vary according to risk factor. STUDY DESIGN: We performed a secondary analysis of the Maternal-Fetal Medicine Units Network randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in high-risk women. Serum biomarker levels at enrollment (before initiation of aspirin or placebo) were compared between women who did and did not develop preeclampsia, both for the group as a whole and within each of 4 high-risk groups (insulin-dependent diabetes, hypertension, multiple gestation, and previous preeclampsia) using a regression model adjusting for gestational age at collection and prepregnancy body mass index. RESULTS: 1258 women were included (233 with insulin-dependent diabetes, 387 with chronic hypertension, 315 with a multiple gestation, 323 with previous preeclampsia). Multiple early pregnancy serum biomarkers differed between women who did and did not develop preeclampsia. Each high-risk group had a unique and largely nonoverlapping pattern of biomarker abnormality. Differences between those who did and did not develop preeclampsia were noted in vascular cell adhesion molecule in the diabetes group; humanchorionic gonadotropin, soluble tumor necrosis factor receptor-2, tumor necrosis factor-alpha, selectin and angiogenin in the chronic hypertension group; interleukin-6, placental growth factor, soluble fms-like tyrosine kinase plus endoglin to placental growth factor ratio in the multiple gestation group; and angiogenin in the previous preeclampsia group. CONCLUSION: Patterns of serum biomarkers vary by high-risk group. These data support the hypothesis that multiple pathogenic pathways lead to the disease recognized clinically as preeclampsia.
Authors: J Hauth; B Sibai; S Caritis; P VanDorsten; M Lindheimer; M Klebanoff; C MacPherson; M Landon; R Paul; M Miodovnik; P Meis; M Dombrowski; G Thurnau; S Walsh; D McNellis; J M Roberts Journal: Am J Obstet Gynecol Date: 1998-11 Impact factor: 8.661
Authors: Sharon E Maynard; Sybil L Crawford; Susanne Bathgate; Jing Yan; Laura Robidoux; Melissa Moore; Tiffany A Moore Simas Journal: Am J Obstet Gynecol Date: 2013-03-18 Impact factor: 8.661
Authors: Baha Sibai; Roberto Romero; Mark A Klebanoff; Madeline Murguia Rice; Steve Caritis; Marshall D Lindheimer; J Peter Van Dorsten; Mark Landon; Menachem Miodovnik; Mitchell Dombrowski; Paul Meis Journal: Am J Obstet Gynecol Date: 2009-06 Impact factor: 8.661
Authors: Gaea S Moore; Amanda A Allshouse; Virginia D Winn; Henry L Galan; Kent D Heyborne Journal: Pregnancy Hypertens Date: 2015-06-23 Impact factor: 2.899
Authors: Matias C Vieira; Shahina Begum; Paul T Seed; Dania Badran; Annette L Briley; Carolyn Gill; Keith M Godfrey; Deborah A Lawlor; Scott M Nelson; Nashita Patel; Naveed Sattar; Sara L White; Lucilla Poston; Dharmintra Pasupathy Journal: Pregnancy Hypertens Date: 2018-07-10 Impact factor: 2.899